Sign up for Breaking News Email Alerts

About Cell Therapy Pharmaceuticals ShareThis Contact Us


Press Releases

Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072006

2013 Archives

11/12/2013
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
10/10/2013
Dr. Eva Feldman, Principal Investigator, to Give Update on ALS Trial at American Neurological Association Meeting
10/09/2013
University Of Michigan Health System Treats Its First Patients In Neuralstem's Phase II ALS Stem Cell Trial
First of Five Cohorts Completed in Dose Escalation Trial
09/26/2013
Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress
Ted Harada, ALS Stem Cell Trial Patient, To Talk
09/10/2013
First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial
09/05/2013
Neuralstem To Raise $4 Million In Registered Direct Offering
09/03/2013
Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
Live Webcast on Tuesday, September 10, at 11:40 a.m. EST
08/09/2013
Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
08/01/2013
Neuralstem Cells Reverse Cognitive Defect In Brain-Irradiated Rats, University Of California Irvine Paper Shows
06/10/2013
Neuralstem ALS Trial Principal Investigator, Dr Eva Feldman, Gives Grand Plenary Address At The Canadian Neurological Sciences Federation Annual Congress
Will Present Final ALS Phase I Results Including New Cervical Cohort Data
05/28/2013
Neuralstem's Cells Induce Improvement In Acute Spinal Cord Injury Rats, UCSD Study Shows
05/20/2013
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
Data Shows, Early Stem Cell Transplantation Could Slow Progression Or Even Improve Patient's Condition in Some Forms of ALS
05/16/2013
Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London
05/13/2013
Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress
05/10/2013
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
05/08/2013
Neuralstem ALS Trial Investigator And Patient On Sirius XM
Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial
04/29/2013
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Method of intraspinal cell delivery found to be safe, well-tolerated, and promising for other spinal cord conditions
04/24/2013
Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment
Investigating feasibility of NSI-189 trial to treat cognitive and psychiatric impairment from traumatic brain injury
04/22/2013
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
04/18/2013
Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
04/17/2013
Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis
Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing
04/05/2013
Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
03/25/2013
Neuralstem Secures $8 Million In Debt Financing From Hercules
03/15/2013
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
03/14/2013
Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"
1-25      26-29
 

print rss

Privacy and Terms ©Neuralstem, Inc. 2016

Information for Investors

ShareThis Copy and Paste